Banach, M., Penson, P. E., Vrablik, M., Bunc, M., Dyrbus, K., Fedacko, J. ... Reiner, Ž. (2021). Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 166.. doi: 10.1016/j.phrs.2021.105499
Banach, Maciej, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research, vol. 166, 2021. https://doi.org/10.1016/j.phrs.2021.105499
Banach, Maciej, Peter E. Penson, Michal Vrablik, Matjaz Bunc, Krzysztof Dyrbus, Jan Fedacko, Dan Gaita, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research 166 (2021). https://doi.org/10.1016/j.phrs.2021.105499
Banach, M., et al. (2021) 'Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)', Pharmacological Research, 166. doi: 10.1016/j.phrs.2021.105499
Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, and sur.. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research [Internet]. 2021 April [cited 2024 December 21];166. doi: 10.1016/j.phrs.2021.105499
M. Banach, et al., "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)", Pharmacological Research, vol. 166, April 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:914316. [Accessed: 21 December 2024]